Lidocream Plus
Product Images NDC 86089-200

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Lidocream Plus (NDC 86089-200). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aec Consumer Products, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxicaine Packaging (Duloxicaine Packaging)

Packaging label for Duloxicainetm by V2 Pharma, showing a prescription medication with Duloxetine Capsules 30 mg (30 count) and Lidocaine HCL Cream (96.4 grams). The label features a blue and white design with the V2 Pharma logo and NDC 72835-802-02. Storage and manufacturing details are visible, but the labeler is not indicated on the packaging.*

FDA Label Image

Structure (C5b0f981 45c3 4e15 B712 984b4a4f6a57 01)

Chemical structure diagram depicting the molecule of lidocaine hydrochloride, showing atom connectivity including aromatic rings, a sulfur heterocycle, and an amine with associated hydrochloride.*

FDA Label Image

Figure 1 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 02)

A Kaplan-Meier curve chart showing the proportion of patients with relapse over time (days) comparing Treatment with Duloxetine versus Placebo. The x-axis represents time from randomization to relapse in days, and the y-axis represents the proportion of patients experiencing relapse, ranging from 0.0 to 1.0. The graph includes two curves: a solid line for Duloxetine and a dashed line for Placebo.*

FDA Label Image

Figure 2 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 03)

A Kaplan-Meier survival curve depicting the proportion of patients with relapse over time (days) from randomization. The graph compares two treatment groups: Placebo (dashed line) and Duloxetine (solid line), showing relapse rates over approximately 250 days.*

FDA Label Image

Figure 1 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 04)

A line graph showing the percentage of patients improved against percent improvement in pain from baseline for four groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and Placebo. The graph compares pain improvement scores across these treatment groups.*

FDA Label Image

Figure 2 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 05)

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. Three lines represent Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo, with the Duloxetine groups showing higher patient improvement rates compared to placebo across various pain improvement percentages.*

FDA Label Image

Fig 5 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 06)

A line chart showing the percentage of patients improved based on percent improvement in pain from baseline. It compares Duloxetine 60 mg taken twice daily, Duloxetine 60 mg taken once daily, and a placebo group, illustrating varying levels of patient improvement across these categories.*

FDA Label Image

Fig 6 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 07)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Duloxetine 120 mg twice daily, Duloxetine 60 mg once daily (two different data sets), and placebo. The y-axis represents the percentage of patients improved, while the x-axis shows percent improvement in pain, ranging from greater than 0 to 100 percent.*

FDA Label Image

Figure 8 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 08)

A line chart showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). The chart compares placebo and Duloxetine 60/120 mg once daily, showing higher patient improvement percentages for Duloxetine at most pain improvement levels.*

FDA Label Image

Figure 9 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 09)

A line graph comparing the percentage of patients improved at varying levels of percent pain improvement from baseline (BOCF) for two groups: Placebo and Duloxetine 60 mg once daily. The x-axis shows percent improvement in pain, and the y-axis shows the percentage of patients improved. Duloxetine consistently shows higher patient improvement percentages across the pain improvement spectrum compared to placebo.*

FDA Label Image

Figure 10 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 10)

A line graph showing the percentage of patients improved in relation to percent improvement in pain from baseline (BOCF). It compares two groups: a placebo group and a group taking Duloxetine 60/120 mg once daily. The x-axis represents the percent improvement in pain from >0 to 100%, and the y-axis represents the percentage of patients improved from 0 to 100%. The Duloxetine group consistently shows higher patient improvement percentages across all pain improvement levels compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.